pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·Oct 22·1 min read
save

Researchers identify cellular stress trigger behind Angelman syndrome

Oct 22, 2026·read at Fierce Biotech ↗Positive

Researchers at Washington University School of Medicine in St. Louis reported a new mechanism linking loss of the maternal UBE3A gene to neuronal stress in Angelman syndrome.

The study, published in Nature on Oct. 21, shows that the absence of UBE3A causes neurons to activate a stress response, which interferes with normal brain development in infants.

Angelman syndrome, a rare neurodevelopmental disorder characterized by intellectual disability, facial features, motor deficits, epilepsy and microcephaly, results from loss-of-function of the maternal UBE3A copy while the paternal copy remains silenced.

Understanding this stress pathway may guide future therapeutic strategies aimed at preventing the brain growth failure that defines the disease.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Why researchers may have found the biological culprit behind Angelman syndrome”

read at Fierce Biotech ↗
512 words · retrieved 14h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.5Washington University School of Medicine4LEADING2IONIS PHARMACEUTICALS INCUNIQUE
drugs
Rare Disease
topics
Rare Disease5Antisense Oligonucleotide (ASO)3Epilepsy2

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Sep 4Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipelineFierce Biotech
  • Sep 3FDA Approves First Drug to Treat Alexander Diseasefda press
  • Oct 8A mother-daughter quest to find fellow members of an ultra-rare genetic communitySTAT
  • Sep 3FDA approves Ionis’ antisense drug as first targeted therapy for Alexander diseaseBioSpace